可孚医疗（301087）7月11日在电话会议上表示，二季度整体经营状况保持正常运转，市场需求相对稳 定。从单品来看，助听业务、居家检测试剂(如胃幽门螺杆菌检测、生育检测等)、敷料敷贴类、成人护 理类等产品增长较快。其中，可孚自研呼吸机表现尤为突出，目前在抖音平台销量位居第一。(人民财 讯) ...

投资者关系活动记录表 编号：2025-005 | 投资者关系活动类 | ☑特定对象调研 □分析师会议 | | --- | --- | | 别 | □媒体采访 ☐业绩说明会 | | | □新闻发布会 □路演活动 | | | ☐现场参观 | | | ☑其他 电话会议 | | 参与单位名称及人 | 招商基金、华夏基金、天弘基金、中银基金、西部利得基金、浦银安盛基金、 | | 员姓名 | 嘉实基金、Dymon Asia、Mighty Divine、宝盈基金、博时基金、汇添富基金、 | | | 泰康资产、大成基金、大家资产、德邦基金、新华资产、中航基金、中加基金、 | | | 中欧基金、东方自营、东吴证券、峰岚资产、茂源财富、尚诚资产、赋远投资、 | | | 高毅资产、盘京投资、工银瑞信基金、华能贵诚信托、国金证券、国盛证券、 | | | 远信基金、长安基金、和谐汇一、华安证券、淳厚基金、华融基金、华西自营、 | | | 华夏久盈、汇华理财、混沌投资、健顺投资、金信基金、金鹰基金、凯石基金、 | | | 南方基金、名禹资产、明河投资、宁银理财、青骊投资、青榕资产、华创证券、 | | | 仁桥资产、华福证券、冰河资产、上 ...

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Meihao Medical, which closed at 18.72 yuan, up 3.83%, with a rolling PE ratio of 29.78, marking a new low in 28 days, and a total market capitalization of 10.649 billion yuan [1] - In comparison to the industry, Meihao Medical's PE ratio of 29.78 is significantly lower than the average PE ratio of 52.06 and the median of 37.22 within the medical device sector, ranking 66th among its peers [1][2] - As of June 30, 2025, Meihao Medical had 12,487 shareholders, an increase of 119 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1] Group 2 - Meihao Medical specializes in the design, development, manufacturing, and sales of precision components and products for medical devices, including home ventilator components and cochlear implant components [1] - The latest quarterly report for Q1 2025 shows that the company achieved a revenue of 296 million yuan, a year-on-year increase of 5.05%, while net profit was 51.875 million yuan, reflecting a year-on-year decrease of 10.62%, with a gross profit margin of 39.28% [1]

Industry Overview - The non-invasive ventilator market in China is experiencing continuous growth due to an aging population, increasing chronic respiratory disease patients, and heightened health management awareness among residents [1][9] - In 2024, the production of non-invasive ventilators in China is projected to reach 672,200 units, a year-on-year increase of 2.50%, while the demand is expected to be 602,700 units, growing by 8.20% [9][11] - The transformation of home non-invasive ventilators from "medical devices" to "health consumer products" aligns with the trend of consumption upgrades [1][9] Industry Development History - The development of the non-invasive ventilator industry in China has gone through four stages: initial stage (1980s-1990s), independent research and development (2000-2010), localization (2010-2020), and the current stage focusing on intelligence and personalization [4][5] - The initial stage saw domestic companies introducing foreign technology but faced challenges such as high production costs and low market share [4] - The current stage emphasizes smart, portable designs, with products like the AI medical product "E5 series" launched by companies like Yihua Jiaye [5] Market Size - The market size of the non-invasive ventilator industry in China is projected to reach 4.856 billion yuan in 2024, reflecting a year-on-year growth of 8.61% [11] - The competitive landscape is shifting, with domestic brands like Ruimaite and Yihua Jiaye gaining market share against international brands [11] Key Companies - Beijing Ruimaite Medical Technology Co., Ltd. ranks among the top five global non-invasive ventilator companies, with over 830 patents and products in more than 180 countries [16] - Jiangsu Yiyue Medical Equipment Co., Ltd. is a leading domestic medical device manufacturer, with a strong presence in the non-invasive ventilator market [18] Industry Trends - The industry is witnessing a wave of technological innovation and product upgrades, with advancements in AI and IoT leading to smarter and more portable non-invasive ventilators [20] - Market demand is expected to continue growing due to the aging population and increasing prevalence of chronic respiratory diseases [21][22] - The competitive landscape is characterized by domestic companies narrowing the gap with international brands, with potential for greater global market share [23]

创新长坡厚雪，医药新章甫开——医药行业 2025 年度中 期投资策略 20250710 摘要 Q&A 2025 年中期医药行业的投资策略是什么？ 2025 年中期医药行业的投资策略主要围绕创新出海和内需复苏两条主线。创 新出海方面，重点关注创新药及其上游产业链，包括 CXO（合同研发与生产组 织）等领域，认为这些板块具有长期配置价值。内需复苏方面，在逆全球化背 景下，建议关注自主可控方向及关税关联度较小的内需板块，以及院内设备更 新逐步落地、电生理、骨科等耗材领域。此外，中药和医药新消费赛道也值得 关注。 2025 年一季度国内上市医药公司的业绩表现如何？ 2025 年一季度国内上市医药公司的整体收入同比增速为-4.2%，归母净利润 同比增速为-8.7%，扣非归母净利润同比增速为-10%。尽管收入端和盈利端承 受一定阶段性压力，但随着前期行业压力逐步释放、创新产品加速放量以及国 中药领域关注中药创新药和品牌 OTC 机会。中药材价格回落，公司库存 水平有望缓解，毛利率受益。关注以岭悦康等公司多条管线进入临床阶 段，以及白云山雪之康、马应龙痔疮膏等品牌 OTC 品种。 医疗器械市场关注设备更新及院内复苏情况，重 ...

"概念验证"是近年来我国科技界的一个热词，旨在打通科技成果转化的"最初一公里"。上海出台的 《关于进一步深化改革创新 加快科技服务业高质量发展的若干意见》提出：要创新概念验证建设运营 模式，建立市场化运营、风险共担和利益共享机制，强化技术与市场可行性"双验证"功能。 在这一改革进程中，上海科技服务平台机构取得了哪些进展？机构负责人有什么建言？记者近日采 访了国家技术转移东部中心、长三角国家技术创新中心。两家机构都设立了概念验证资金，打造了概念 验证平台，推动科研人员和临床医生的创新成果转化为新质生产力。 "翻译员"接洽资本独当一面 在体系化服务中，技术经理人扮演着重要角色。孙剑峰介绍，上海国际绿色低碳概念验证中心的15 位持证技术经理人来自复旦大学、上海交通大学、同济大学、哥伦比亚大学、爱丁堡大学等名校，专业 背景都是环境科学或绿色低碳技术。经过高级技术经理人培训，他们学会了技术转移服务，成为既懂技 术语言又懂市场语言的"翻译员"。 记者 俞陶然 体系化服务科研概念验证 上海国际绿色低碳概念验证中心由国家技术转移东部中心与复旦大学共建，集聚了35位复旦科研人 员、200余位研究生和科研助理以及15位持证技术经 ...

Company Overview - Beijing Ruimait Medical Technology Co., Ltd. specializes in the manufacturing of medical devices and consumables in the respiratory health sector, with key products including various types of sleep breathing machines and monitoring devices [1] - The company holds a total of 633 domestic patents, including 107 invention patents and 390 utility model patents, as well as 202 international patents across multiple countries [1] Financial Performance - For Q1 2025, the company reported a revenue of 265 million yuan, representing a year-on-year increase of 38.11%, and a net profit of 71.93 million yuan, up 44.11% year-on-year [2] - The company's gross profit margin stands at 49.57% [2] Market Position - As of July 4, the company's stock closed at 83.14 yuan, with a rolling price-to-earnings (PE) ratio of 41.99, while the average PE ratio in the medical device industry is 51.05 [1][2] - The company's total market capitalization is 7.449 billion yuan [1] Capital Flow - On July 4, the company experienced a net outflow of 3.0578 million yuan in principal funds, with a total outflow of 370,800 yuan over the past five days [1]

7月4日，美好医疗今日收盘18.05元，上涨1.69%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到28.71倍，总市值102.68亿元。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13美好医疗28.7128.232.92102.68亿行业平均 51.0548.784.55107.12亿行业中值36.6236.522.5051.67亿1九安医疗10.2610.380.81173.21亿2英科医疗 10.4711.290.93165.45亿3新华医疗14.4313.381.1892.52亿4奥美医疗15.3215.011.5755.35亿5山东药玻 15.3915.431.77145.53亿6振德医疗15.4714.580.9856.17亿7康德莱15.7315.741.3033.89亿8维力医疗 16.4917.141.9337.60亿9九强生物16.4915.332.0281.66亿10奥泰生物16.6117.511.3452.96亿11安杰思 17.6117.812.1352.26亿12安图生物18.8317.982.42214.74亿 来源：金融界 从行业市盈率排名来看，公司 ...

Core Insights - The company reported a revenue of 36.726 billion yuan in 2024, reflecting a growth of 5.14%, with a net profit attributable to shareholders of 11.668 billion yuan, up by 0.74% [1] - In Q4 2024, the company experienced a revenue decline of 5.08% to 7.241 billion yuan, while net profit surged by 40.99% to 1.031 billion yuan [1] - The first quarter of 2025 saw a revenue drop of 12.12% to 8.237 billion yuan, with net profit decreasing by 16.81% to 2.629 billion yuan [1] Financial Performance - The overall gross margin for 2024 was 63.14%, a decrease of 1.08%, primarily due to changes in business structure and product pricing adjustments [2] - The company’s operating cash flow for 2024 was 12.432 billion yuan, an increase of 12.38% [1] - The gross margin for Q1 2025 improved by 6.57 percentage points to 62.53%, indicating that short-term adjustments may have been largely absorbed [2] Business Segments - The Life Information and Support segment generated 13.557 billion yuan in 2024, a decline of 11.11%, but the minimally invasive surgery business grew by over 30% [3] - The In Vitro Diagnostics segment achieved a revenue of 13.765 billion yuan, up by 10.82%, despite domestic challenges due to policy changes [3] - The Medical Imaging segment reported a revenue of 7.498 billion yuan, reflecting a growth of 6.60%, with high-end ultrasound models contributing significantly [3] International Expansion - The company’s international business grew by 21.28% in 2024, accounting for approximately 45% of total revenue, driven by high-end customer acquisition and local platform development [2] - The In Vitro Diagnostics international business saw over 30% growth, with local production projects initiated in 13 countries [3] Research and Development - The company maintained high R&D investment levels, with 4.008 billion yuan in 2024, representing 10.91% of revenue [4] - As of March 31, 2025, the company had applied for approximately 12,000 patents, with 5,973 patents granted [4] Shareholder Returns - The company distributed a total cash dividend of 7.602 billion yuan in 2024, with a cash dividend ratio of 65.15% [4] - A mid-term profit distribution plan for 2025 proposes a cash dividend of 1.710 billion yuan, reflecting strong profitability and commitment to shareholder returns [4]

Core Viewpoint - The company reported a decline in revenue and net profit for 2024, primarily due to high base effects from 2023 and adjustments in the respiratory therapy business, while showing growth in certain segments in Q1 2025 [1][2]. Financial Performance - For 2024, the company achieved revenue of 7.566 billion yuan (-5.09%), net profit attributable to shareholders of 1.806 billion yuan (-24.63%), and operating cash flow of 1.816 billion yuan (-14.61%) [1]. - In Q1 2025, the company reported revenue of 2.436 billion yuan (+9.18%), net profit of 625 million yuan (-5.26%), and operating cash flow of 658 million yuan (+2.64%) [1][2]. Business Segment Analysis - The respiratory therapy segment generated revenue of 2.597 billion yuan, with certain products experiencing declines due to high base effects, while home respiratory devices and nebulizers showed growth [2]. - The blood glucose management and POCT business achieved revenue of 1.03 billion yuan (+40.21%), with significant growth in CGM products [2]. - The home health measurement segment reported revenue of 1.564 billion yuan (-0.41%), with some products declining due to high base effects, while others like electronic blood pressure monitors saw double-digit growth [2]. - The clinical and rehabilitation business generated revenue of 2.093 billion yuan (+0.24%), with good growth trends in acupuncture needles and wheelchairs, but a decline in infection control products due to demand fluctuations [2]. - The emergency business reported revenue of 239 million yuan (+34.05%), with self-developed AED products achieving certification and further technical upgrades [2]. Strategic Initiatives - The company made a strategic investment of $27.21 million in Inogen, acquiring a 9.9% stake, to expand its market presence in Europe and the US, leveraging Inogen's established production bases and market share [3]. - The partnership with Inogen will focus on distribution cooperation for various respiratory products and aims to enhance product exports and collaborative R&D efforts [3]. Dividend Policy - In 2024, the company distributed a total dividend of 802 million yuan, representing 44.40% of net profit attributable to shareholders, reflecting a strong commitment to investor returns and long-term confidence [3]. Investment Outlook - The company is positioned as a leader in home medical devices, focusing on respiratory and oxygen therapy, blood glucose management, and infection control, with an improving product structure and brand advantages [4]. - Forecasts for net profit from 2025 to 2027 are adjusted to 2.341 billion yuan, 2.699 billion yuan, and 3.104 billion yuan, reflecting year-on-year growth of 29.63%, 15.29%, and 15.03% respectively [4].